Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure‐based drug design

PI3Kα remains an attractive target for the development of anticancer targeted therapy. A number of p110α crystal structures in complex with the nSH2‐iSH2 fragment of p85 regulatory subunit have been reported, including a few small molecule co‐crystal structures, but the utilization of this crystal form is limited by low diffraction resolution and a crystal packing artifact that partially blocks the ATP binding site. Taking advantage of recent data on the functional characterization of the lipid binding properties of p110α, we designed a set of novel constructs allowing production of isolated stable p110α subunit missing the Adapter Binding Domain and lacking or featuring a modified C‐terminal lipid binding motif. While this protein is not catalytically competent to phosphorylate its substrate PIP2, it retains ligand binding properties as indicated by direct binding studies with a pan‐PI3Kα inhibitor. Additionally, we determined apo and PF‐04691502 bound crystal structures of the p110α (105‐1048) subunit at 2.65 and 2.85 Å, respectively. Comparison of isolated p110α(105‐1048) with the p110α/p85 complex reveals a high degree of structural similarity, which validates suitability of this catalytically inactive p110α for iterative SBDD. Importantly, this crystal form of p110α readily accommodates the binding of noncovalent inhibitor by means of a fully accessible ATP site. The strategy presented here can be also applied to structural studies of other members of PI3KIA family.

[1]  Juswinder Singh,et al.  Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. , 2013, Journal of medicinal chemistry.

[2]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[3]  Bert Vogelstein,et al.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.

[4]  P. Vogt,et al.  Cancer-specific mutations in phosphatidylinositol 3-kinase. , 2007, Trends in biochemical sciences.

[5]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[6]  S. Lesley,et al.  High-throughput Protein Production for X-ray Crystallography and Use of Size Exclusion Chromatography to Validate or Refute Computational Biological Unit Predictions , 2005, Journal of Structural and Functional Genomics.

[7]  B. Vogelstein,et al.  Structural effects of oncogenic PI3Kα mutations. , 2010, Current topics in microbiology and immunology.

[8]  P. Hawkins,et al.  PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.

[9]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[10]  Li Zhao,et al.  Phosphatidylinositol 3-kinase: the oncoprotein. , 2010, Current topics in microbiology and immunology.

[11]  J. Backer,et al.  Regulation of class IA PI3Ks. , 2007, Biochemical Society transactions.

[12]  Glenn R Masson,et al.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA) , 2012, Proceedings of the National Academy of Sciences.

[13]  P. Vogt.  PI3K p110β: more tightly controlled or constitutively active? , 2011, Molecular cell.

[14]  Roger L. Williams,et al.  Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism , 2011, Molecular cell.

[15]  Aileen McHarg,et al.  PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity , 2011, Molecular Cancer Therapeutics.

[16]  M. Pairish,et al.  Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series. , 2013, Bioorganic & medicinal chemistry letters.

[17]  John E. Burke,et al.  Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases , 2011, Science Signaling.

[18]  John E. Burke,et al.  Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS) , 2013, Advances in biological regulation.

[19]  J. Backer,et al.  Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit , 1998, Molecular and Cellular Biology.

[20]  Robbie Loewith,et al.  A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39 , 2006 .

[21]  Roger L. Williams,et al.  Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases , 2011, Oncogene.

[22]  P. Vogt,et al.  Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α , 2010, Proceedings of the National Academy of Sciences.

[23]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[24]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.